Docetaxel-related interstitial pneumonitis

Szczegóły
Opis

Tytuł:: Docetaxel-related interstitial pneumonitis
Autorzy:: Wang CJ
Chang HT
Chang CY
Temat:: Docetaxel
Interstitial lung disease
Therapeutics. Pharmacology
RM1-950
Źródło:: Therapeutics and Clinical Risk Management, Vol 2015, Iss Issue 1, Pp 1813-1816 (2015)
Wydawca:: Dove Medical Press, 2015.
Rok publikacji:: 2015
Kolekcja:: LCC:Therapeutics. Pharmacology
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 1178-203X
Relacje:: https://www.dovepress.com/docetaxel-related-interstitial-pneumonitis-peer-reviewed-article-TCRM; https://doaj.org/toc/1178-203X
Dostęp URL:: https://doaj.org/article/d3114846ed084ed4a7e2dea3b3185cd2 Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.3114846ed084ed4a7e2dea3b3185cd2
: Czasopismo naukowe

Pełny tekst

Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Abstract: Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration. Keywords: docetaxel, interstitial lung disease

Informacja